StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX - Free Report) in a report issued on Friday. The brokerage issued a hold rating on the stock.
Brooklyn ImmunoTherapeutics Stock Performance
NYSE:BTX traded up $0.19 during trading hours on Friday, reaching $6.71. The stock had a trading volume of 1,123,818 shares, compared to its average volume of 840,859. The stock has a market capitalization of $394.72 million, a PE ratio of -2.96 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 52 week low of $6.35 and a 52 week high of $8.31. The company has a 50 day moving average price of $2.62 and a two-hundred day moving average price of $1.51.
Brooklyn ImmunoTherapeutics Announces Dividend
The firm also recently disclosed a monthly dividend, which will be paid on Monday, March 31st. Shareholders of record on Friday, March 14th will be given a dividend of $0.0862 per share. The ex-dividend date of this dividend is Friday, March 14th. This represents a $1.03 annualized dividend and a yield of 15.41%. Brooklyn ImmunoTherapeutics's dividend payout ratio (DPR) is currently -40.09%.
About Brooklyn ImmunoTherapeutics
(
Get Free Report)
Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.
Read More
Before you consider Brooklyn ImmunoTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Brooklyn ImmunoTherapeutics wasn't on the list.
While Brooklyn ImmunoTherapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
